Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia

Ibrutinib, an irreversible small-molecule inhibitor of both Bruton's tyrosine kinase (BTK) and interleukin-2 inducible kinase (ITK), has shown outstanding efficacy in controlling relapsed/refractory and/or previously untreated CLL [1,2]. Although the exact mechanisms are not completely understood, there is a growing body of evidence about the immunomodulating effects of ibrutinib on different immune cell types and signalling pathways in various types of hematologic and solid cancers [3,4,5]. In CLL, ibrutinib has been shown to abrogate CLL cell trafficking, signalling, and adhesion in response to tissue homing chemokines such as CXCL12 and CXCL13 [6,7,8].

Source: Leukemia Research - August 10, 2018 Category: Hematology Authors: Gayane Manukyan, Peter Turcsanyi, Zuzana Mikulkova, Gabriela Gabcova, Renata Urbanova, Petr Gajdos, Veronika Smotkova Kraiczova, Sarka Zehnalova, Tomas Papajik, Eva Kriegova Tags: Research paper Source Type: research